Skip to main content

News stories

New support through pregnancy with launch of birth preferences card

Published on 10/09/2024

A new birth preferences card has been launched at UHB
A new birth preferences card has been launched at UHB

A birth preferences card is helping new parents across maternity services at UHB.

The card, which was originally developed at The Shrewsbury and Telford Hospital NHS Trust, enables service users to discuss birth preferences with their care team and support partners.

The card also aims to assist clinicians to have a clear visual guide of women’s preferences during their birth experience.

Service users are given at their 25 to 28 week appointment with time to consider personal preferences before completing it with their midwife at their 34 to 36 week appointment.

This is then kept under review and amended if needed at a later appointment with their midwife or doctor. The card stays with them throughout their birthing journey to ensure their preferences are known by their care team and it can be amended at any stage as clinical needs or preferences change.

Large whiteboard versions of the card have been installed in all birth rooms and induction bays across our services.

This means a woman’s birth preferences can be circled and shown in a clear position in the birthing room, enabling clinicians to see a woman’s preferences at a glance.

If you have any questions about the birth preferences card, email: Annie.lester@uhb.nhs.uk

More news

Members of the UHB Chaplaincy Team receive their award.

Excellence award presented to Chaplaincy Team

Birmingham Council of Faiths presented an award in recognition of outstanding chaplaincy teamwork

UHB named top NHS employer for apprenticeships

The Trust has marked another milestone for learners by earning a place in the Top 100 Apprenticeship Employers for 2024

The Clinical Research Facility Team at QEHB

Birmingham hospital first in Europe to enrol a patient in new investigational pancreatic cancer vaccine trial

Queen Elizabeth Hospital has enrolled the first patient in Europe into a new trial investigating a therapeutic mRNA-based “pancreatic cancer vaccine”.

Read more news